For research use only. Not for therapeutic Use.
Adrixetinib (TFA)(CAT: I040302) is a small-molecule inhibitor of protein tyrosine kinases with demonstrated antineoplastic activity. By targeting key signaling enzymes involved in tumor growth and progression, Adrixetinib disrupts aberrant phosphorylation cascades that drive cancer cell proliferation, survival, and metastasis. Its mechanism of action includes the inhibition of tyrosine kinase-mediated pathways, making it a promising candidate for therapeutic intervention in tyrosine kinase-driven malignancies. Supplied as a trifluoroacetate (TFA) salt to enhance solubility and formulation stability, Adrixetinib is suitable for preclinical studies in oncology and kinase-targeted drug discovery.
| Synonyms | N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-1-propyl-4-(2,2,2-trifluoroethoxy)pyrazole-3-carboxamide;2,2,2-trifluoroacetic acid |
| Molecular Formula | C27H25F6N5O7 |
| Purity | ≥95% |
| IUPAC Name | N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-1-propyl-4-(2,2,2-trifluoroethoxy)pyrazole-3-carboxamide;2,2,2-trifluoroacetic acid |
| InChI | InChI=1S/C25H24F3N5O5.C2HF3O2/c1-4-9-33-13-21(37-14-25(26,27)28)23(32-33)24(34)31-22-6-5-15(12-30-22)38-18-7-8-29-17-11-20(36-3)19(35-2)10-16(17)18;3-2(4,5)1(6)7/h5-8,10-13H,4,9,14H2,1-3H3,(H,30,31,34);(H,6,7) |
| InChIKey | JDZQIIDIZOVHIM-UHFFFAOYSA-N |
| SMILES | CCCN1C=C(C(=N1)C(=O)NC2=NC=C(C=C2)OC3=C4C=C(C(=CC4=NC=C3)OC)OC)OCC(F)(F)F.C(=O)(C(F)(F)F)O |
| Chemistry Calculators | Dilution Calculator In vivo Formulation Calculator Molarity Calculator Molecular Weight Calculator Reconstitution Calculator |
